Journal of Nuclear Medicine: 66 (2)

February 1, 2025; Volume 66,Issue 2

Cover image

FEATURED ARTICLE

¹⁷⁷Lu-DOTATATE Plus Capecitabine Versus ¹⁷⁷Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. Swayamjeet Satapathy et al. See page 238.

In this issue

Issue highlights

¹⁷⁷Lu-DOTATATE Plus Capecitabine Versus ¹⁷⁷Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial
RadioFlow Cytometry Reveals That [¹⁸F]FDG Uptake in K-RAS Lung Cancer Is Driven by Immune Cells: An Analysis on a Single-Cell Level

MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
Prediction of ¹⁷⁷Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to